CagriSema in Biohacking for Weight Loss
CagriSema is an experimental combination drug from Novo Nordisk designed to treat type 2 diabetes and obesity. It combines semaglutide (the active ingredient in Wegovy/Ozempic) and cagrilintide, administered as a weekly injection to significantly reduce appetite and body weight. Our biohacking experts explain what makes it innovative and how it works.
Contents
Highlights
- CagriSema combines semaglutide and cagrilintide for better weight loss resullts
- It reduces appetite and increases fullness through two different hormone pathways
- The combination works better than each component used on its own
- CagriSema is still experimental and not yet approved
What is CagriSema
The active ingredient in Ozempic and Wegovy is semaglutide. The only difference between these two brands is the dosage. Both products are well-suited for their intended purposes. That is why their sales are growing rapidly. In the first quarter, Ozempic’s revenue reached 27.8 billion Danish kroner ($4.1 billion), up 42% from the same period last year. Wegovy’s revenue of 9.4 billion Danish kroner ($1.3 billion) rose 106% year over year.
But what if Novo Nordisk could offer a treatment that is even more effective than these two? Meet CagriSema, an experimental drug for diabetes and obesity that the company is testing in Phase 3 trials.
While Ozempic, for example, mimics only one hormone — GLP-1 — CagriSema is a “fixed-dose combination,” combining two powerful substances in a single weekly injection: semaglutide, the active ingredient in Ozempic and Wegy, and cagrilintide: a long-acting analog of amylin, a hormone that regulates hunger and blood sugar levels after meals.
What is Cagrilintide
Cagrilintide is an innovative synthetic long-acting analog of the hormone amylin, developed for weight loss and the treatment of obesity. It regulates blood sugar levels, reduces appetite, and slows gastric emptying. It is often used in combination with semaglutide (CagriSema) to enhance its effect. Cagrilintide is considered a promising next-generation treatment for metabolic disorders.
Unlike popular GLP-1 receptor agonist drugs, such as semaglutide, cagrilintide works through a completely different mechanism, triggering a feeling of fullness and reducing calorie intake.
What is Semaglutide
Semaglutide is a highly effective GLP-1 receptor agonist (a hormone analog). Originally developed to treat type 2 diabetes, it quickly gained popularity as an effective weight-loss treatment. It mimics a hormone that lowers blood sugar levels, slows stomach emptying, and suppresses appetite, helping to reduce weight by 10–15% or more. Popular medications: Ozempic, Rybelsus (tablets), Quinsenta, Semavik.
Semaglutide lowers blood glucose levels by stimulating glucose-dependent insulin secretion and suppressing glucagon secretion. Thus, when blood glucose levels rise, insulin secretion is stimulated, and glucagon secretion is suppressed.
Semaglutide reduces total body weight and fat mass by decreasing energy intake. This mechanism involves a general reduction in appetite, including enhanced satiety signals and weakened hunger signals, as well as improved control over food intake and reduced food cravings. Insulin resistance is also reduced, possibly due to weight loss. In addition, semaglutide reduces the preference for high-fat foods. Animal studies have shown that semaglutide is taken up by specific brain regions and enhances key satiety signals while attenuating key hunger signals. By acting on specific regions of the brain, semaglutide activates neurons associated with satiety and suppresses those associated with hunger.
In clinical trials, semaglutide improved plasma lipid levels, lowered systolic blood pressure, and reduced inflammation.
In animal studies, semaglutide inhibits the progression of atherosclerosis by preventing the further growth of aortic plaques and reducing plaque inflammation.
How Cagrilintide and Semaglutide Work Together
It turns out that when used together (in the drug CagriSema), semaglutide and cagrilintide work synergistically, resulting in greater weight loss (about 20% or more) than either drug alone.
Semaglutide (a GLP-1 agonist) reduces appetite. It slows gastric emptying, while cagrilintide (an amylin analog) enhances the feeling of fullness and regulates glucagon levels by acting on other brain areas.
CagriSema vs Other Weight Loss Drugs
The new generation of anti-obesity drugs is shifting from single-hormone therapies to multi-receptor approaches, significantly improving weight-loss outcomes. CagriSema, tirzepatide, and retatrutide represent three distinct strategies — dual combination, dual agonism, and triple agonism — each targeting different metabolic pathways. Below is a side-by-side comparison of their mechanisms, efficacy, and current regulatory status.
|
Factor |
CagriSema |
Tirzepatide |
Retatrutide |
|
Receptors Targeted |
Amylin + GLP-1 |
GLP-1 + GIP (dual agonist) |
GLP-1 + GIP + Glucagon (triple agonist) |
|
Average Weight Loss |
~20.4–22.7% at 68 weeks (source) |
~21–25.5% at 72 weeks (SURMOUNT trials, widely reported benchmark) |
~24–28.7% at 48–68 weeks (source) |
|
FDA Status |
No (investigational, late-stage trials) |
Yes (approved) |
No (investigational, Phase 3) |
|
Brands |
None |
Zepbound®, Mounjaro® |
None |
Clinical Trials of CagriSema
CagriSema is a combination of semaglutide and another compound called cagrilintide. Both drugs are effective in treating diabetes and help patients lose weight. There is clinical evidence that combining these two drugs enhances their effectiveness. In a Phase 2 study of people with type 2 diabetes, Novo Nordisk compared CagriSema with semaglutide and cagrilintide. After 32 weeks of treatment, CagriSema was more effective at lowering blood glucose levels and body weight than its individual components — semaglutide and cagrilintide.
In the same study, CagriSema trial results showed better impact compared to semaglutide. However, this was an interim study. CagriSema still needs to undergo further studies.
Cagrilintide also demonstrated a favorable safety profile in all clinical trials. Side effects, such as nausea and temporary stomach discomfort, were mild and transient. This makes the drug suitable for long-term use.
FDA Approval Status of CagriSema
As of 2026, CagriSema remains an investigational drug and is not yet FDA-approved, with regulatory submission expected following completion of its Phase 3 program (according to the Drugs.com CagriSema history page).
The Phase 3 REDEFINE clinical program demonstrates strong efficacy:
- REDEFINE 1 (non-diabetic patients) showed ~20.4% average weight loss at 68 weeks (up to ~22.7% with full adherence), confirming high efficacy.
- REDEFINE 2 (patients with type 2 diabetes) also met primary endpoints, confirming significant weight reduction versus placebo.
- REDEFINE 4 (head-to-head vs trizepatide) achieved ~23% weight loss but did not meet its primary comparative endpoint.
Meanwhile, REDEFINE 3 (cardiovascular outcomes) and REDEFINE 11 are ongoing, aiming to further evaluate long-term efficacy and safety.
To sum up
CagriSema is a promising combination drug from Novo Nordisk intended for the treatment of obesity and type 2 diabetes, which is positioned as a more potent successor to the popular drug Wegovy (semaglutide). The CagriSema blend’s potential is based on the combination of two active ingredients: semaglutide (a GLP-1 analog) and cagrilintide (an amylin analog) in the form of a weekly injection. As of early 2026, the drug has not been approved by the FDA; however, Novo Nordisk submitted an application for approval in December 2025.
for subscribing!